drugset
Drugs / Peripheral blood stem cells
last change Apr 2024 re-read 8 days ago

Peripheral blood stem cells

also known as PBSC

Cell therapy

Developed for
myelodysplastic syndrome · acute myeloid leukemia · acute myocardial infarction · articular cartilage disorder · Burkitt lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic myeloid leukemia · follicular lymphoma
+10 more · HIV infectious disease · lymphoblastic lymphoma · lymphoplasmacytic lymphoma · mantle cell lymphoma · non-Hodgkin lymphoma · paroxysmal nocturnal hemoglobinuria · plasma cell leukemia · plasma cell myeloma · prolymphocytic leukemia · chronic granulomatous disease
Investigated by
DKMS · Kuala Lumpur Sports Medicine Centre · Masonic Cancer Center, University of Minnesota · Ministry of Science, Technology and Innovation (MOSTI) Malaysia · National Heart, Lung, and Blood Institute (NHLBI) · Ribozyome
+1 more · Seoul National University Hospital

Trials 6

today NCT03520647 · Ph 2 NCT03275636 · Ph 2/3 NCT02661035 · Ph 2 NCT01076673 · Ph 2 NCT00501917 · Ph 2/3
2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials
Phase 2 NCT03520647 Feb 2019 → Jun 2027 expected myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria National Heart, Lung, and Blood Institute (NHLBI) Recruiting No outcome recorded
Phase 2 NCT02661035 Mar 2017 → Apr 2023 Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +8 Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Phase 2 NCT01076673 Oct 2009 → May 2012 articular cartilage disorder Kuala Lumpur Sports Medicine Centre Completed No outcome recorded
Phase 2 NCT00002221 — HIV infectious disease, non-Hodgkin lymphoma Ribozyome Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT03275636 Jan 2018 → Apr 2024 acute myeloid leukemia, myelodysplastic syndrome DKMS Completed No outcome recorded
Phase 2/3 NCT00501917 Mar 2007 → Feb 2010 acute myocardial infarction Seoul National University Hospital Unknown No outcome recorded
Comparator or background therapy2 trials
Phase 1/2 NCT02629120 Comparator Dec 2015 → Dec 2027 expected chronic granulomatous disease National Institute of Allergy and Infectious Diseases (NIAID) Active not recruiting No outcome recorded
Phase 3 NCT01445821 Background Sep 2011 → Jan 2017 systemic sclerosis Northwestern University Terminated No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Peripheral Blood Stem Cells “intracoronary infusion of peripheral blood stem cells mobilized with G-CSF” PMID 21299845 ↗ Feb 2011
7

“Peripheral Blood Stem Cells” NCT03520647 ↗

NCT02661035 ↗

NCT01076673 ↗

NCT02629120 ↗

NCT00002221 ↗

NCT01445821 ↗

NCT03275636 ↗
Known as PBSC “The purpose of this study was to compare histologic and magnetic resonance imaging (MRI) evaluation of articular cartilage regeneration in patients with chondral lesions...” NCT01076673 ↗
Action Restore “replace the patient's immune cells with functional immune cells” NCT02629120 ↗
Modality Cell therapy “the gene-modified and untreated stem cells are infused back into the patient” NCT00002221 ↗
Route Intravenous “The LN and L-TR/Tat-neo samples are pooled and given to the patient by IV infusion over about 15 minutes.” NCT00002221 ↗